Bordetella pertussis
Brand names: Adacel · Active ingredient: Bordetella Pertussis Toxoid Antigen (Glutaraldehyde Inactivated), Bordetella Pertussis Filamentous Hemagglutinin Antigen (Formaldehyde Inactivated), Bordetella Pertussis Pertactin Antigen
In short: Adacel® is a vaccine indicated for: Active booster immunization against tetanus, diphtheria and pertussis. Adacel is approved for use in individuals 10 through 64 years of age.
What is Bordetella pertussis used for?
Adacel® is a vaccine indicated for:
Active booster immunization against tetanus, diphtheria and pertussis. Adacel is approved for use in individuals 10 through 64 years of age.
Immunization during the third trimester of pregnancy to prevent pertussis in infants younger than 2 months of age.
Bordetella pertussis dosage
For intramuscular use.
Just before use, shake the vial or syringe well until a uniform, white, cloudy suspension results.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If either of these conditions exist, the vaccine should not be administered.
Withdraw the 0.5 mL dose of vaccine from the single-dose vial.
Adacel should not be combined through reconstitution or mixed with any other vaccine. Discard unused portion in vial.
Administer Adacel intramuscularly as a single 0.5 mL dose.
Routine Booster Vaccination
A first dose of Adacel is administered 5 years or more after the last dose of the Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) series or 5 years or more after a dose of Tetanus and Diphtheria Toxoids Adsorbed (Td). A second dose of Adacel may be administered 8 years or more after the first dose of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap).
Vaccination During the Third Trimester of Pregnancy
To prevent pertussis in infants younger than 2 months of age, administer Adacel to pregnant individuals during the third trimester of pregnancy.
Wound Management
Adacel may be administered for tetanus prophylaxis for wound management. For management of a tetanus prone wound, a booster dose of Adacel may be administered if at least 5 years have elapsed since previous receipt of a tetanus toxoid containing vaccine.
When Adacel is administered concomitantly with other injectable vaccines or Tetanus Immune Globulin, they should be given with separate syringes and at different injection sites.
How to take Bordetella pertussis — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Before administration of Adacel, inform the patient, parent or guardian of the benefits and risks of the vaccine and the importance of receiving recommended booster dose unless a contraindication to further immunization exists.
Inform the patient, parent or guardian about the potential for adverse reactions that have been temporally associated with Adacel or other vaccines containing similar components.
Provide the Vaccine Information Statements (VISs) that are required by the National Childhood Vaccine Injury Act of 1986 to be given with each immunization.
Instruct the patient, parent or guardian to report any adverse events to their healthcare provider or to the Vaccine Adverse Event Reporting System at 1-800-822-7967 and https://vaers.hhs.gov.
Pregnancy Exposure Registry
Women who receive Adacel during pregnancy are encouraged to contact directly, or have their healthcare professional contact, Sanofi Vaccines US Inc. at 1-800-822-2463 (1-800-VACCINE) or online at https://www.sanofivaccinespregnancyregistry.com.
Warnings & precautions
Do not take this medicine if: A severe allergic reaction (e.g., anaphylaxis) after a previous dose of any tetanus toxoid, diphtheria toxoid or pertussis containing vaccine or any other component of this vaccine is a contraindication to administration of Adacel. Because of uncertainty as to which component of the vaccine may be responsible, none of the components should be administered. Alternatively, such individuals may be referred to an allergist for evaluation if further immunizations are to be considered.
Encephalopathy (e.g., coma, prolonged seizures, or decreased level of consciousness) within 7 days of a previous dose of a pertussis containing vaccine not attributable to another identifiable cause is a contraindication to administration of any pertussis containing vaccine, including Adacel.
Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of Adacel.
If Guillain-Barré syndrome occurred within 6 weeks of receipt of prior vaccine containing tetanus toxoid, the risk for Guillain-Barré syndrome may be increased following a dose of Adacel. A review by the Institute of Medicine found evidence for acceptance of a causal relation between tetanus toxoid and brachial neuritis. (1)
Progressive or unstable neurologic conditions are reasons to defer Adacel. It is not known whether administration of Adacel to persons with an unstable or progressive neurologic disorder might hasten manifestations of the disorder or affect the prognosis. Administration of Adacel to persons with an unstable or progressive neurologic disorder may result in diagnostic confusion between manifestations of the underlying illness and possible adverse effects of vaccination. …
Bordetella pertussis side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to vaccine use and for approximating rates of those events. As with any vaccine, there is the possibility that broad use of Adacel could reveal adverse reactions not observed in clinical trials.
The safety of a first vaccination with Adacel was evaluated in 5 clinical studies. Three of the studies were conducted in the U.S. and 2 were conducted in Canada. Of the study participants, 86% were Caucasian, 8% Black, 3% Hispanic, 1% Asian and 2% of other ethnic origin. A total of 7,143 individuals 10 through 64 years of age inclusive (4,695 adolescents 10 through 17 years of age and 2,448 adults 18 through 64 years of age) received a single dose of Adacel.
U.S. Adolescent and Adult Study of a First Vaccination with Adacel (Td506)
Clinical study Td506 was a randomized, observer-blind, active-controlled trial that enrolled adolescents 11 through 17 years of age (Adacel N = 1,184; DECAVAC (Tetanus and Diphtheria Toxoids Adsorbed; manufactured by Sanofi Vaccines US Inc., Swiftwater, PA) N = 792) and adults 18 through 64 years of age (Adacel N = 1,752; DECAVAC N = 573). …
Drug interactions
No interference in tetanus and diphtheria seroprotection rates and responses to influenza vaccine, detoxified pertussis toxin (PT), fimbriae types 2 and 3 (FIM) or filamentous hemagglutinin (FHA) were observed when Adacel vaccine was administered concomitantly with TIV compared to separate administration. A lower pertactin (PRN) GMC was observed when Adacel was administered concomitantly with TIV compared to separate administration .
About this medicine
Adacel is a sterile isotonic injectable suspension of tetanus and diphtheria toxoids and pertussis antigens adsorbed on aluminum phosphate, for intramuscular use.
Each 0.5 mL dose contains 5 Lf tetanus toxoid (T), 2 Lf diphtheria toxoid (d), and acellular pertussis antigens [2.5 mcg detoxified pertussis toxin (PT), 5 mcg filamentous hemagglutinin (FHA), 3 mcg pertactin (PRN), 5 mcg fimbriae types 2 and 3 (FIM)]. Other ingredients per 0.5 mL dose include 1.5 mg aluminum phosphate (0.33 mg aluminum) as the adjuvant, ≤5 mcg residual formaldehyde, <50 ng residual glutaraldehyde and 3.3 mg (0.6% v/v) 2-phenoxyethanol (not as a preservative). The antigens are the same as those in DAPTACEL; however, Adacel is formulated with reduced quantities of diphtheria and detoxified PT.
The acellular pertussis vaccine components are produced from Bordetella pertussis cultures grown in Stainer-Scholte medium (2) modified by the addition of casamino acids and dimethyl-beta-cyclodextrin. PT, FHA and PRN are isolated separately from the supernatant culture medium. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID a41b7601-34f2-4a88-a406-f53011fb7de1. Read the full official label on DailyMed.